Taladegib for the treatment of idiopathic pulmonary fibrosis (ENV-IPF-101): a multicentre, randomised, double-blind, placebo-controlled, phase 2a trial

By afschroeder • October 4, 2025

Maher TM, Goldin JG, Hood J, Pitman J, de Los Rios M, Hobbs BP, Yu-Lin AB, Buendia-Roldan I, Thien F, Song JW, Perea PC, Ramírez-Rivera A, DiFrancesco A. Taladegib for the treatment of idiopathic pulmonary fibrosis (ENV-IPF-101): a multicentre, randomised, double-blind, placebo-controlled, phase 2a trial. Lancet Respir Med. 2025 Sep 30:S2213-2600(25)00239-5. doi: 10.1016/S2213-2600(25)00239-5. Epub ahead of print. PMID: 41043447.

Tags: Publications, Pulmonary, Critical Care & Sleep Medicine

Hand Swelling and Other Non-Raynaud Phenomenon Symptoms as the Initial Presentation of Systemic Sclerosis: Prevalence and Clinical Associations in Two US Cohorts

Hanif I, Assassi S, Mayes MD, McMahan ZH, Zhang M, Charles J, VanBuren JM, Alvey JS, Ghaffari K, Bernstein EJ, Castelino FV, Chung L, Evnin[...]

Augmenting management of obstructive sleep apnea with consumer wearable devices to increase use of positive airway pressure therapy: a pilot randomized trial

Fung CH, Mak S, Ash G, Der-McLeod E, Ereso J, Naeem S, Liu J, Ghadimi S, Te TT, Chan V, Hurtado J, Wong S, Zeidler[...]

Viral Infections and Risk of Cardiovascular Disease: Systematic Review and Meta-Analysis

Kawai K, Muhere CF, Lemos EV, Francis JM. Viral Infections and Risk of Cardiovascular Disease: Systematic Review and Meta-Analysis. J Am Heart Assoc. 2025 Oct[...]